搜尋結果
2021年4月22日 · Ambroxol is a mucolytic compound and the main ingredient of over-the-counter cough medicines sold in many countries. Syrup, tablet, and other forms are used at doses of 30 to 120 mg per day to reduce or thin mucous secretions and ease sore throat pain. The most common side effects are gastrointestinal.
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol. 2020 Apr 1;77(4):427-434. PubMed. Recommends Please login to recommend the .
2018年3月6日 · Consistent with TDP-43 autoregulation, a decrease in endogenous murine levels was observed in transgenic mice. Transgene expression was highest in the brain and spinal cord with very low levels observed in other tissues. At birth, the TDP-43 Q331K mice were indistinguishable from non-Tg littermates. Tremor was observed as early as three to four ...
A Phase 2 trial has been approved by the Food and Drug Administration and will begin enrolling this month, with completion scheduled for 2022, Sardi said. The study will enroll about 230 people who have Parkinson’s and a GBA mutation. Although this initial trial only includes mutation carriers, the researchers believe the strategy may work to ...
Therapeutics. This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at therapeutics@alzforum.org.
2022年5月3日 · Vodobatinib is a third-generation c-Ableson tyrosine kinase inhibitor. It is structurally similar to the commercial anticancer agents Dasatinib and Ponatinib (Antelope et al., 2019). Abl kinase inhibitors induce autophagy, leading to the death of rapidly dividing cells (Salomoni and Calabretta, 2009).
Venglustat is a brain-penetrant allosteric inhibitor of the enzyme glucosylceramide synthase. GCS catalyzes an early step in the synthesis of many glycolipids. Venglustat is being developed for lysosomal storage diseases, including Gaucher’s, Fabry, and for Parkinson’s caused by mutations in the GBA1 gene.
Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24.060 ACI-3024 ACI-35 ACI-7104.056
Alzheimer's Disease (Discontinued) Denali Therapeutics Inc., Takeda Pharmaceutical Company. Amyloid-Related, Inflammation. Immunotherapy (passive) Docosahexaenoic acid (DHA) Omega-3 fatty acid. Alzheimer's Disease (Phase 4) Martek Biosciences Corporation, NeuroBioPharm, Inc.
Therapeutics. This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at therapeutics@alzforum.org.
